We are live on ! Find out more
REVB icon

Revelation Biosciences

8 hedge funds and large institutions have $540K invested in Revelation Biosciences in 2025 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 2 increasing their positions, 3 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

740% more capital invested

Capital invested by funds: $64.2K → $540K (+$476K)

50% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 2

14% more funds holding

Funds holding: 78 (+1)

3.33% more ownership

Funds ownership: 0.74%4.06% (+3.3%)

33% less repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 3

Holders
8
Holders Change
+1
Holders Change %
+14.29%
% of All Funds
0.1%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
3
Increased
2
Reduced
3
Closed
2
Calls
Puts
Net Calls
Net Calls Change

REVB Hedge Fund Activity: Q3 2025 in Review

8 of the 7,624 institutional investors tracked by Wall St. Rank reported a position in Revelation Biosciences (REVB) for Q3 2025, worth a combined $540K — up 740% from $64.2K a quarter earlier.

Buyers outnumbered sellers: 3 funds opened new REVB positions and 2 closed out — a net gain of 1 holder — while 2 added to existing stakes and 3 trimmed.

The largest buyer was Sabby Management, adding an estimated $449K. The largest seller was StoneX Group, exiting entirely with an estimated $7.66K sold.

  • 8 institutional investors held Revelation Biosciences (REVB) as of Q3 2025, up from 7 in Q2 2025.
  • Funds reported $540K of Revelation Biosciences stock for Q3 2025, up 740% quarter-over-quarter.
  • 3 funds opened new Revelation Biosciences positions in Q3 2025 and 2 closed out, a net change of +1 holder.
  • The largest Revelation Biosciences buyer in Q3 2025 was Sabby Management, an estimated $449K added.
  • The largest Revelation Biosciences seller in Q3 2025 was StoneX Group, an estimated $7.66K sold.

Based on aggregated 13F filings for Q3 2025.